Incyte Co. (NASDAQ:INCY) Stock Holdings Reduced by TD Asset Management Inc

Posted by on May 5th, 2023

TD Asset Management Inc lowered its position in Incyte Co. (NASDAQ:INCY – Get Rating) by 2.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 138,974 shares of the biopharmaceutical company’s stock after selling 3,524 shares during the quarter. TD Asset Management Inc owned approximately 0.06% of Incyte worth $11,162,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Cetera Advisor Networks LLC lifted its position in shares of Incyte by 7.4% during the 1st quarter. Cetera Advisor Networks LLC now owns 5,265 shares of the biopharmaceutical company’s stock worth $418,000 after purchasing an additional 362 shares during the last quarter. Private Advisor Group LLC bought a new stake in shares of Incyte in the 1st quarter valued at approximately $323,000. D.A. Davidson & CO. grew its stake in shares of Incyte by 4.8% in the 1st quarter. D.A. Davidson & CO. now owns 3,300 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 150 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in shares of Incyte by 6.8% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 25,172 shares of the biopharmaceutical company’s stock valued at $1,999,000 after purchasing an additional 1,605 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in shares of Incyte by 7.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 596,022 shares of the biopharmaceutical company’s stock valued at $47,338,000 after purchasing an additional 43,168 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on INCY shares. Cowen upped their price objective on Incyte from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday, February 8th. Mizuho decreased their price target on Incyte from $95.00 to $82.00 in a research report on Wednesday. SVB Leerink restated an “underperform” rating and set a $63.00 price target on shares of Incyte in a research report on Wednesday, February 8th. BMO Capital Markets decreased their price target on Incyte from $75.00 to $70.00 in a research report on Wednesday. Finally, William Blair restated an “outperform” rating on shares of Incyte in a research report on Monday, March 20th. One analyst has rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $81.50.

Incyte Stock Performance

INCY stock opened at $66.19 on Friday. The business’s fifty day moving average is $73.61 and its 200-day moving average is $77.41. The company has a quick ratio of 3.50, a current ratio of 3.95 and a debt-to-equity ratio of 0.01. The company has a market cap of $14.77 billion, a P/E ratio of 45.65, a price-to-earnings-growth ratio of 2.97 and a beta of 0.72. Incyte Co. has a twelve month low of $65.07 and a twelve month high of $86.29.

Incyte (NASDAQ:INCY – Get Rating) last issued its quarterly earnings data on Tuesday, February 7th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.59 by $0.03. The business had revenue of $926.70 million for the quarter, compared to the consensus estimate of $880.25 million. Incyte had a return on equity of 9.99% and a net margin of 9.35%. The firm’s revenue was up 7.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.07) EPS. Equities research analysts forecast that Incyte Co. will post 3.28 EPS for the current year.

Incyte Profile

(Get Rating)

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Featured Stories

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.